Open Journal Systems

Ovarian carcinoma: An overview of current status

Yogita Lugani ()
Smita Asthana ()
Satyanarayana Labani ()

Abstract


Ovarian carcinoma is one of the leading causes of morbidity and mortality associated with carcinomas affecting women. It comprises a heterogeneous group of neoplasms that represents the seventh most lethal malignancy in women worldwide, and is a major cause of death from gynecological carcinoma. Specific to different geographical locations all over the globe, there are variations in the magnitude and trends of ovarian carcinoma, and the scenario of the disease keeps changing. As such, it is necessary to update and review the existing study on ovarian carcinoma. Reviews on ovarian cancer from 2000 to 2015 were extracted from PubMed and Google Scholar, and a few selected landmark studies that incorporated old data were also included. The focus of the present study is to consolidate an updated global view on epithelial ovarian carcinoma, the most prevalent type of ovarian carcinoma. This article covers the epidemiology, types, diagnosis, prognosis, and treatment of epithelial ovarian carcinoma.

Keywords


ovarian carcinoma; epidemiology; diagnosis; prognosis; treatment

Full Text:

PDF

References


Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, et al. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 2007; 23(5–6): 367–376. doi: 10.1155/2007/ 474320.

Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26(6): 995–1005. doi: 10.1200/JCO.2006.07.9970.

Fathalla MF. Incessant ovulation – A factor in ovarian neoplasia? Lancet 1971; 298(7716): 163. doi: 10.1016/ S0140-6736(71)92335-X.

Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem 1995; 59(Suppl 23): 200–207. doi: 10.1002/jcb.240590927.

Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991; 12(1): 14–26. doi: 10.1210/edrv-12-1-14.

Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Carcinoma Inst 1998; 90(23): 1774– 1786. doi: 10.1093/jnci/90.23.1774.

Kuroda H, Mandai M, Konishi I, Tsuruta Y, Kusakari T, et al. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2001; 91(3): 309–315. doi: 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1¬0-60>3.0.CO;2-0.

Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer – A short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007; 269(1–2): 61–64. doi: 10.1016/ j.mce.2006.11.014.

Bonello N, McKie K, Jasper M, Andrew L, Ross N, et al. Inhibition of nitric oxide: Effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Biol Reprod 1996; 54(2): 436–445. doi: 10.1095/biolreprod54.2.436.

The oncology committee of the International Federation of Gynecology and Obstetrics. FIGO news: Changes to the 1985 FIGO report on the result of treatment in gy-naecological cancer. Int J Gynecol Obstet 1987; 25(1): 87–88. doi: 10.1016/0020-7292(87)90233-5.

National Ovarian Cancer Coalition [Internet]. Dallas, Texas. [cited 2015 Oct 17]. Available from: http://www. ovarian.org/types_and_stages.php.

McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathol2011; 43(5): 420–432. doi: 10.1097/PAT.0b013e328348a6e7.

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma — Evidence supporting the clonal relationship of the two le-sions. J Pathol 2012; 226(3): 421–426. doi: 10.1002/ path.3023.

Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993; 71(Suppl S2): 566– 572. doi: 10.1002/cncr.2820710212.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: Cancer J Clin 2011; 61(4): 212–236. doi: 10.3322/caac.20121.

Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015; 3: 7. doi: 10.1186/s40425-015- 0051-7.

Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010; 34(3): 433–443. doi: 10.1097/PAS. 0b013e3181cf3d79.

Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. BioMed Res Int 2014; 2014: 934261. doi: 10.1155/2014/934261.

Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 2010; 194(2): 311–321. doi: 10.2214/ AJR.09.3522.

Burges A, Schmalfeldt B. Ovarian cancer: Diagnosis and treatment. Dtsch Arztebl Int 2011; 108(38): 635–641. doi: 10.3238/arztebl.2011.0635.

Ezzati M,Abdullah A,Shariftabrizi A, Hou J, Kopf M, et al. Recent advancements in prognostic factors of epithelial ovarian carcinoma. Int Sch Res Notices 2014; 2014: 953509. doi: 10.1155/2014/953509.

Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012; 23 (Suppl 10): x118–x127. doi: 10.1093/annonc/mds315.

Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109(10): 3921–3926.doi: 10.1073/pnas.1117135109.

Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013; 5(2): 133–141. doi: 10.1177/ 1758834012467661.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2015 Nov 25]. Available from: http://globocan.iarc.fr.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. [cited 2015 Nov 22]. Available from: http://glo-bocan.iarc.fr.

Angelina Jolie's effect: Risk factors for ovarian cancer! [Internet]. India: Zee Media Corporation Ltd. [cited 2015 Oct 17]. Available from: http://zeenews.india.com/news/ health/diseases-conditions/angelina-jolies-effect-risk-factors-for-ovarian-carcinoma_1566989.html.

SEER Cancer Statistics Review 1975–2013. [Internet]. USA: National Cancer Institute; 2010. [cited 2015 Nov 20]. Available from: http://seer.cancer.gov/archive/ csr/1975_2013/results_merged/topic_survival.pdf.

Ovarian cancer statistics. [Internet]. Washington, DC: Ovarian Cancer National Alliance; 2015. [cited 2015 Nov 20]. Available from: http://www.ovariancancer.org/wp- content/uploads/2015/06/Statistics-2015_final.pdf.

Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, et al. (German) [Krebs in Deutschland: 2005/2006; Häufigkeiten und trends; Eine gemeinsame Veröffen-tlichung des Robert Koch-Instituts und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.]. Berlin: Robert Koch-Institut; 2010. Available from: http: //www.rki.de/DE/Content/Gesundheitsmonitoring/Gesun-dheitsberichterstattung/GBEDownloadsB/KID2010.pdf?_blob=publicationFile.

Shih IM, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164(5): 1511–1518. doi: 10.1016/S0002-9440(10)63708-X.

McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008; 61(2): 152–163. doi: 10.1136/jcp.2007.049478.

Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008; 27(2): 161–174. doi: 10.1097/PGP.0b013e31815ea812.

Three year report of population based cancer registries 2012-2014: Incidence, distribution, trends in incidence rates and projections of burden of cancer. [Internet]. Bengaluru, India: National Centre for Disease Informatics and Research, National Cancer Registry Programme, and Indian Council Medical Research. [cited 2016 May 2016]. Available from: http://www.ncrpindia.org/ALL_NCRP_ REPORTS/PBCR_REPORT_2012_2014/ALL_CONTENT/Printed_Version.htm.

Lagos VI, Perez MA, Ricker CN, Blazer KR, Santiago NM, et al. Social-cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psychooncology 2008; 17(8): 774–782. doi: 10.1002/pon.1358.

Ricciardelli C, Oehler MK. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009; 62(3): 270–275. doi: 10.1016/j.maturitas.2009. 01.001.

Schuijer M, Berns EMJJ. TP53 and ovarian cancer. Hum Mutat 2003; 21(3): 285–291. doi: 10.1002/humu.10181.

Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991; 49(1): 50–56. doi: 10.1002/ijc. 2910490110.

Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991; 49(1): 57–60. doi: 10.1002/ijc. 2910490111.

Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991; 49(1): 61–65. doi: 10.1002/ijc. 2910490112.

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343(8899): 692–695. doi: 10.1016/S0140-6736(94)91578-4.

Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo Urrutia R, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Re-port/Technology Assessment No. 212. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC033- EF. [Internet]. Rockville, MD: Agency for Healthcare Research and Quality. [cited 2015 Oct 20]. Available from: https://effectivehealthcare.ahrq.gov/ehc/products/416/1530/cancer-ovarian-contraceptives-executive-130611.pdf.

Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, et al. Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol 2013; 122(1): 139–147. doi: 10.1097/AOG.0b013e318291c235.

Tomao F, Russo GL, Spinelli GP, Stati V, Prete AA, et al. Fertility drugs, reproductive strategies and ovarian cancer risk J Ovarian Res 2014; 7: 51. doi: 10.1186/1757- 2215-7-51.

Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140(7): 585–597.

Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer — Shifting the paradigm. Hum Pathol 2011; 42(7): 918–931. doi: 10.1016/j.humpath.2011.03.003.

Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJJ, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195(4): 451– 456. doi: 10.1002/path.1000.

Piek JMJ, Kenemans, P, Verheijen RHM. Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004; 191(3): 718–732. doi: 10.1016/j.ajog.2004.02.067.

Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, et al. Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol 2010; 29(3): 273–277. doi: 10.1097/PGP. 0b013e3181c30301.

Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (non-uterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34(10): 1407–1416. doi: 10.1097/PAS.0b013e3181ef7b16.

Royal College of Pathologists. Datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum. London: Royal College of Pathologists; 2008.

Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganised orphan papillae. Int J Gynecol Pathol 2010; 29(6): 507– 512. doi: 10.1097/PGP.0b013e3181e31f74.

Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopath-ologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16(5): 267–282. doi: 10.1097/PAP.0b013e3181b4fffa.

Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23(1): 41–44. doi: 10.1097/01.pgp.0000101080.35393.16.

Köbel M, Kalloger SE, Santos JL, Huntsman DG, Blake Gilks C, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol 2010; 116(1): 50–56. doi: 10.1016/ j.ygyno.2009.09.029.

Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103(3): 1122– 1129. doi: 10.1016/j.ygyno.2006.08.012.

Benito V, Lubrano A, Arencibia O, Medina N, Eva EA, et al. Serous and mucinous borderline ovarian tumors: Are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 2010; 153(2): 188–192. doi: 10.1016/j.ejogrb.2010.07.024.

Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95(6): 484–486. doi: 10.1093/jnci/ 95.6.484.

Tan DSP, Kaye S. Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol 2007; 60(4): 355–360. doi:10.1136/jcp.2006.040030.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363(16): 1532–1543. doi: 10.1056/NEJMoa1008433.

Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol2000; 24(11): 1465–1479. doi: 10.1097/ 00000478-200011000-00002.

Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, et al. Malignancy in endometriosis: Frequency and com-parison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20(2): 133–139. doi: 10.1097/00004347- 200104000-00004.

Obata K, Morland SJ, Watson RH, Hitchcock A, Chen-evix-Trench G, et al. Frequent PTEN/MMAC1 mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58(10): 2095–2097.

Catasús L, Bussaglia E, Rodríguez I, Gallardo A, Pons C, et al. Molecular genetic alterations in endometrioid car-cinomas of the ovary: Similar frequency of beta-cat¬enin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35(11): 1360–1368. doi: 10. 1016/j.humpath.2004.07.019.

Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, et al. Advances in the recognition of tubal intra-epithelial carcinoma: Applications to cancer screening and the pathogenesis of ovarian carcinoma. Adv Anat Pathol 2006; 13(1): 1–7. doi: 10.1097/01.pap.000020182 6.46978.e5.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211(1): 26–35. doi: 10.1002/path.2091.

Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31(2): 161–169. doi: 10.1097/01.pas. 0000213335.40358.47.

Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010; 220(1): 5–6. doi: 10.1002/ path.2630.

Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM. Muta-tions of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64(19): 6915–6918. doi: 10.1158/0008-5472.CAN-04-2067.

Sieben NLG, Macropoulos P, Roemen GMJM, Kolkman-Uljee SM, Jan Fleuren G, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202(3): 336– 340. doi: 10.1002/path.1521.

Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, et al. Patterns of p53 mutations separate ovarian serous border-line tumors and low- and high-grade carcinomas and pro-vide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29(2): 218–224. doi: 10.1097/01.pas.0000146025.91953.8d.

Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28(4): 496–504. doi: 10.1097/00000478-200404000-00009.

Sala E. Ovarian cancer: imaging in treatment selection and planning with FIGO update. Cancer Imaging 2014; 14(Suppl 1): 018. doi: 10.1186/1470-7330-14-S1-O18.

Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006; 26(1): 647–653.

Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351(24): 2519–2529. doi: 10.1056/NEJMra041842.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010; 116(3): 378– 383. doi: 10.1016/j.ygyno.2009.10.087.

Skates, SJ. Ovarian cancer screening: Development of the Risk of Ovarian Cancer Algorithm(ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012; 22(Suppl 1): S24–S26. doi: 10.1097/IGC.0b013e318256488a.

FIGO ovarian cancer staging. [Internet]. [cited 2015 Aug 15]. Available from: https://www.sgo.org/wp-content/ up-loads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf.

Fehrmann RSN, Li XY, van der Zee AGJ, de Jong S, te Meerman GJ, et al. Profiling studies in ovarian cancer: A review. Oncologist 2007; 12(8): 960–966. doi: 10.1634/theoncologist.12-8-960.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25(5): 517–525. doi: 10.1200/JCO. 2006.06.3743.

Ahmed FY,Wiltshaw E, A’Hern RP, Nicol B, Shepherd J, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14(11): 2968–2975.

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357(9251): 176–182. doi: 10. 1016/S0140-6736(00)03590-X.

Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95; 155-163. doi: 10.1056/NEJM199002083220602.

Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374(9698): 1371–1382. doi: 10.1016/ S0140-6736(09)61338-6.

Parker WH, Broder MS, Chang E, Feskanich DS, Far-quhar C, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 2009; 113(5): 1027–1037. doi: 10.1097/AOG.0b013e3181a11c64.

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVA R-2.2 trial. Lancet 2003; 361(9375): 2099–2106. doi: 10.1016/ S0140-6736(03)13718-X.

Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis. Cancer Treat Rev 2012; 38(6): 613–617. doi: 10.1016/j.ctrv.2011.10.008.

Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91(6): 747-754. doi:10.1002/bjs.4473.

Kuhn E, Tisato V, Rimondi E, Secchiero P. Current pre-clinical models of ovarian cancer. J Carcinog Mutagen 2015; 6(2): 220. doi: 10.4172/2157-2518.1000220.

De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, et al. Immunotherapy of ovarian cancer: The role of checkpoint inhibitors. J Immunol Res 2015; 2015: 1-7. doi: 10.1155/2015/191832.

McCabe N, Turner NC, Lord CJ, Kluzek K, Białkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66(16): 8109–8115. doi: 10.1158/0008-5472. CAN-06-0140.

Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian carcinoma: A Phase I study. Clin Cancer Res 2010; 16(21): 5288–5295. doi: 10.1158/1078-0432.CCR-10-0700.

Seoung J, Park Y, Rhim C, Kim S. Current possible drug therapies for ovarian cancer. J Cancer Ther 2014; 5: 1203–1214. doi: 10.4236/jct.2014.513122.

Lipkowitz S, Kohn EC. To treat or not to treat: The use of hormone replacement therapy in patients with ovarian cancer. J Clin Oncol 2015; 33(35): 4127–4128. doi: 10.1200/JCO.2015.63.6670.

Chen RF, Li J, Zhu TT, Yu HL, Lu X. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): Single institution experience. J Ovarian Res 2016; 9: 16. doi: 10.1186/s13048-016-0226-y.

Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, et al. Fertility sparing surgery in early stage epithelial

ovarian cancer. J Gynecol Oncol 2014; 25(4): 320–327. doi: 10.3802/jgo.2014.25.4.320.

Seong SJ, Kim DH, Kim MK, Song T.Controversies in borderline ovarian tumors. J Gynecol Oncol 2015; 26(4): 343–349. doi: 10.3802/jgo.2015.26.4.343.

Holderfield M, Deuker MM, McCormick F,McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14(7): 455–467. doi: 10.1038/nrc3760.

Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016; 3: 3. doi: 10.1186/s40661-016-0024-7.

Vasconcelos I, Gaspar O. Meta-analysis of the PARP inhibitor olaparib reveals therapeutic efficacy in ovarian cancer independent of BRCA1/2 mutation status. Adv Mod Oncol Res 2016; 2(1): 91–96; http://dx.doi.org/ 10.18282/amor.v2.i2.54.

Panguluri SK, Yeakel C, Kakar SS. PTTG: An important target gene for ovarian cancer therapy. J Ovarian Res 2008; 1: 6. doi: 10.1186/1757-2215-1-6.

Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology 2014; 3(10): 958949. doi: 10.4161/21624011.2014.958949.

Azvolinsky A. Anti-PD-1 antibody nivolumab shows activity in ovarian cancer. [Internet]. US: UBM Medica, LLC; 2015. [cited 2015 Aug 15]. Available from: http:// www.cancernetwork.com/gynecologic-cancers/anti-pd-1-antibody-nivolumab-shows-activity-ovarian-cancer.



DOI: http://dx.doi.org/10.30564/amor.v2i5.80

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Yogita Lugani, Smita Asthana, Satyanarayana Labani

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.